21.7 C
New York
Friday, July 30, 2021

Cipla, Lupin may gain from Perrigo’s drug recall, says Macquarie

Must read

Stocks in focus: JK Laxmi Cement, MRPL and more

Business News>Markets>Stocks>News>Stocks in focus: JK Laxmi Cement, MRPL and more Check out the stocks that will be in focus during trade today based on...

Buy Nalco, target price Rs 100: Yes Securities

Yes Securities has buy call on National Aluminium Company Ltd. with a target price of Rs 100. The current market price of National Aluminium...

Gold set for biggest weekly gain in over 2 months on dovish Fed

Gold prices held near a two-week high on Friday, and were set for their biggest weekly gain in more than two months, on renewed...

Wall St gains with upbeat earnings and forecasts; Facebook falls 4%

NEW YORK: US stocks ended higher on Thursday, boosted by robust U.S. earnings and forecasts, while data showed the economy recovered to pre-pandemic levels...

Mumbai: Perrigo Company’s voluntary recall of albuterol sulfate or generic of ProAir in the US may prove to be an unexpected gain for Lupin and Cipla who are Perrigo’s competitors in the $850 million – $900 million US albuterol sulfate market, said foreign brokerage Macquarie.

Perrigo announced the voluntary nationwide recall of albuterol sulfate following complaints that some units may not dispense due to clogging. A definitive timeline for reintroduction has not been determined.

“Perrigo’s competitors in the US$850-900 million (normalised) US Albuterol Sulfate market. While Cipla launched gProventil in Apr-20, Lupin’s gProAir launch is expected this month. Currently, we are building US$40 million and US$60 million sales in FY21 for Lupin and Cipla, respectively,” said Macquarie. “If we assume US$20 million incremental Albuterol sales each for Lupin and Cipla from Sep-20 till Dec-20 due to Perrigo’s recall, there is a 4-6% upside risk to our FY21 EPS estimates for Lupin and Cipla,” said Macquarie.

The foreign brokerage said that if Perrigo’s relaunch is delayed further, the opportunity for Lupin and Cipla will increase further.

Macquarie has maintained an underperform rating on Lupin with a target price of Rs 750. The brokerage said the stock is trading at stretched valuations after the recent run up in stock price.

On Cipla, Macquarie has maintained an outperform rating with a target price of Rs 816. The brokerage expects Cipla to deliver a strong 19% EPS CAGR over FY20-FY23 led by strength across markets and cost efficiences.

- Advertisement -

Latest article

Stocks in focus: JK Laxmi Cement, MRPL and more

Business News>Markets>Stocks>News>Stocks in focus: JK Laxmi Cement, MRPL and more Check out the stocks that will be in focus during trade today based on...

Buy Nalco, target price Rs 100: Yes Securities

Yes Securities has buy call on National Aluminium Company Ltd. with a target price of Rs 100. The current market price of National Aluminium...

Gold set for biggest weekly gain in over 2 months on dovish Fed

Gold prices held near a two-week high on Friday, and were set for their biggest weekly gain in more than two months, on renewed...

Wall St gains with upbeat earnings and forecasts; Facebook falls 4%

NEW YORK: US stocks ended higher on Thursday, boosted by robust U.S. earnings and forecasts, while data showed the economy recovered to pre-pandemic levels...

Buy State Bank of India, target price Rs 465: Yes Securities

Yes Securities has buy call on State Bank of India with a target price of Rs 465. The current market price of State Bank...